According to a study to be presented at the American Society of Clinical Oncology meeting, OSI Pharmaceuticals Inc."s drug Tarceva (erlotinib) slowed the progression of lung cancer when given early in treatment for the disease. In the study, which included 889 patients, 25% of those receiving Tarceva experienced progression-free survival compared to 15% of the placebo group. Notably, progression-free survival improved in patients with non-squamous cell carcinoma as well as more aggressive squamous cell carcinoma.